The safety and efficacy of nicotine replacement therapy in the intensive care unit: a randomised controlled pilot study

Ben de Jong, Anne Sophie Schuppers, Arriette Kruisdijk-Gerritsen, Maurits Erwin Leo Arbouw, Hubertus Laurentius Antonius van den Oever, Arthur R H van Zanten, Ben de Jong, Anne Sophie Schuppers, Arriette Kruisdijk-Gerritsen, Maurits Erwin Leo Arbouw, Hubertus Laurentius Antonius van den Oever, Arthur R H van Zanten

Abstract

Background: Studies evaluating nicotine replacement therapy (NRT) to prevent nicotine withdrawal symptoms in ICU patients have yielded conflicting results. We performed a randomised controlled double-blind pilot study to assess the safety and efficacy of NRT in critically ill patients. Mechanically ventilated patients admitted to two medical-surgical intensive care units and smoking more than 10 cigarettes per day before ICU admission were enrolled in this study. Participants were randomised to transdermal NRT (14 or 21 mg per day) or placebo until ICU discharge or day 30. Smoking status was confirmed by the biomarkers serum cotinine and urinary NNAL. The primary endpoint was 30-day mortality. Among secondary endpoints and post hoc endpoints, 90-day mortality, safety, time spent without delirium, sedation and coma, and patient destination at day 30 were addressed.

Results: We enrolled 47 patients. No differences were found between NRT and control group patients concerning 30-day mortality (9.5 vs. 7.7%, p = 0.84) and 90-day mortality (14.3 vs. 19.2%, p = 0.67). The number of serious adverse events was comparable between groups (NRT: 4, control: 11, p = 0.13). At day 20, average time alive without delirium, sedation and coma was 16.6 days among NRT patients versus 12.6 days among control patients (p = 0.03). At day 30, more NRT group patients were discharged from the ICU or hospital compared with controls (p = 0.03).

Conclusions: NRT did not affect mortality or the number of (serious) adverse events compared with placebo. Time alive without delirium, sedation and coma at day 20 in NRT patients was longer than in control patients. An adequately powered randomised controlled trial to further study safety and efficacy of NRT in ICU patients seems feasible and is warranted. Trial registration ClinicalTrials.gov, number NCT01362959, registered 1 June 2011.

Keywords: Agitation; Cotinine; Delirium; NNAL; Smoking; Withdrawal.

Figures

Fig. 1
Fig. 1
30-Day and 90-day mortality comparing nicotine replacement therapy and placebo group. NRT nicotine replacement therapy
Fig. 2
Fig. 2
Patient destinations at day 30 and day 90 comparing nicotine replacement therapy and placebo group. Data are presented as numbers. ICU intensive care unit, NRT nicotine replacement therapy
Fig. 3
Fig. 3
Patients alive without delirium and without sedation or coma comparing nicotine replacement therapy and placebo group. Data presented as the percentage of time patients were alive without delirium and without sedation or coma (RASS ≥ − 3). NRT nicotine replacement therapy

References

    1. World Health Organization . WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. Geneva: World Health Organization; 2011. p. 8.
    1. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-Century hazards of smoking and benefits of cessation in the united states. N Engl J Med. 2013;368:341–350. doi: 10.1056/NEJMsa1211128.
    1. Trend in roken volwassenen, 1990–2015. . Accessed 11 Jan 2018.
    1. Burden of tobacco use in de U.S.: current cigarette smoking among U.S. adults aged 18 years and older. . Accessed 11 Jan 2018.
    1. Lucidarme O, Seguin A, Daubin C, et al. Nicotine withdrawal and agitation in ventilated critically ill patients. Crit Care. 2010;14(2):R58. doi: 10.1186/cc8954.
    1. Van Rompaey B, Elseviers MM, Schuurmans MJ, et al. Risk factors for delirium in intensive care patients: a prospective cohort study. Crit Care. 2009;13(3):R77. doi: 10.1186/cc7892.
    1. Moller AM, Pedersen T, Villebro N, et al. A study of the impact of long-term tobacco smoking on postoperative intensive care admission. Anaesthesia. 2003;58(1):55–59. doi: 10.1046/j.1365-2044.2003.02788_2.x.
    1. Zaal IJ, Devlin JW, Peelen LM, et al. A systematic review of risk factors for delirium in the ICU. Crit Care Med. 2015;43(1):40–47. doi: 10.1097/CCM.0000000000000625.
    1. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295–2303. doi: 10.1056/NEJMra0809890.
    1. National Center for Chronic Disease Prevention and Health Promotion (US) office on smoking and health. The health consequences of smoking—50 years of progress: a report of the surgeon general. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014. Chapter 5 (Nicotine) and Chapter 8 (Cardiovascular Diseases).
    1. Hatsukami DK, Stead LF, Gupta PC. Tobacco addiction. Lancet. 2008;371(9629):2027–2038. doi: 10.1016/S0140-6736(08)60871-5.
    1. Fagerström KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatment for tobacco withdrawal symptoms. Psychopharmacology. 1993;111(3):271–277. doi: 10.1007/BF02244941.
    1. Mayer SA, Chong JY, Ridgway E, et al. Delirium from nicotine withdrawal in neuro-ICU patients. Neurology. 2001;57(3):551–553. doi: 10.1212/WNL.57.3.551.
    1. Honisett TD. Nicotine replacement therapy for smokers admitted to intensive care. Intensive Crit Care Nurs. 2001;17(6):18–21. doi: 10.1054/iccn.2001.1610.
    1. Lee AH, Afessa B. The association of nicotine replacement therapy with mortality in a medical intensive care unit. Crit Care Med. 2007;35(6):1517–1521. doi: 10.1097/01.CCM.0000266537.86437.38.
    1. Paciullo CA, Short MR, Steinke DT, et al. Impact of nicotine replacement therapy on postoperative mortality following coronary artery bypass graft surgery. Ann Pharmacother. 2009;43(7):1197–1202. doi: 10.1345/aph.1L423.
    1. Panos NG, Tesoro EP, Kim KS, et al. Outcomes associated with transdermal nicotine replacement therapy in a neurosurgery intensive care unit. Am J Health Syst Pharm. 2010;67(16):13571361. doi: 10.2146/ajhp090402.
    1. Cartin-Ceba R, Warner DO, Hays JT, et al. Nicotine replacement therapy in critically ill patients: a prospective observational cohort study. Crit Care Med. 2011;39(7):1635–1640. doi: 10.1097/CCM.0b013e31821867b8.
    1. Seder DB, Schmidt JM, Badjatia N, et al. Transdermal nicotine replacement therapy in cigarette smokers with acute subarachnoid hemorrhage. Neurocrit Care. 2011;14(1):77–83. doi: 10.1007/s12028-010-9456-9.
    1. Gillies MA, McKenzie CA, Whiteley C, et al. Safety of nicotine replacement therapy in critically ill smokers: a retrospective cohort study. Intensive Care Med. 2012;38(10):1683–1688. doi: 10.1007/s00134-012-2604-2.
    1. Kerr A, McVey JT, Wood AM, et al. Safety of nicotine replacement therapy in critically ill smokers: a retrospective cohort study. Anaesth Intensive Care. 2016;44(6):758–761.
    1. Pathak V, Rendon ISH, Lupu R, et al. Outcome of nicotine replacement therapy in patients admitted to ICU: a randomized controlled double-blind prospective pilot study. Respir Care. 2013;58(10):1625–1629. doi: 10.4187/respcare.01791.
    1. Kowalski M, Udy AA, McRobbie HJ, et al. Nicotine replacement therapy for agitation and delirium management in the intensive care unit: a systematic review of the literature. J Intensive Care. 2016;15(4):69. doi: 10.1186/s40560-016-0184-x.
    1. Xia Y, McGuffey JE, Bhattacharyya S, et al. Analysis of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine by extraction on a molecularly imprinted polymer column and liquid chromatography/atmospheric pressure ionization tandem mass spectrometry. Anal Chem. 2005;77(23):7639–7645. doi: 10.1021/ac058027u.
    1. Hsieh SJ, Ware LB, Eisner MD, et al. Biomarkers increase detection of active smoking and secondhand smoke exposure in critically ill patients. Crit Care Med. 2011;39(1):40–45. doi: 10.1097/CCM.0b013e3181fa4196.
    1. Goniewicz ML, Eisner MD, Lazcano-Ponce E, et al. Comparison of urine cotinine and the tobacco-specific nitrosamine metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and their ratio to discriminate active from passive smoking. Nicotine Tob Res. 2011;13(3):202–208. doi: 10.1093/ntr/ntq237.
    1. Horan TC, Andrus M, Duceck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi: 10.1016/j.ajic.2008.03.002.
    1. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–2653. doi: 10.1001/jama.298.22.2644.
    1. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007;9(3):315–327. doi: 10.1080/14622200701188919.
    1. Carroll I, Mount T, Atkinson D. Myocardial infarction in intensive care units: a systematic review of diagnosis and treatment. J Intensive Care Soc. 2016;17(4):314–325. doi: 10.1177/1751143716656642.
    1. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever